At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 322 enrolled
Drug / intervention
trospium chloride +1 moredrug
Likely dose
trospium chloride 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily
In Brief
A Phase 4 clinical trial evaluating trospium chloride and placebo for Overactive Bladder. Completed, enrolled 322 participants across 1 site.
Detailed Summary
This study will investigate the safety and efficacy of Sanctura XR (trospium chloride) daily in reducing urgency, urinary frequency and urinary urge incontinence in female patients with incontinence refractory to Detrol LA (tolterodine tartrate extended release) 4 mg therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2010
First PostedMar 2010
Primary CompletionJun 2012
TodayJul 2026
First PostedMar 19, 2010
Enrollment StartMar 1, 2010
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.3 years ago
Interventions
trospium chloridedrug
Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks
placebodrug
Placebo once daily on an empty stomach for 14 weeks.